Key facts
- This page summarizes Matthew E. Lipman's Form 3 filing for Capstone Holding Corp. (CAPS).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 Apr 2025, 15:53.
Matthew E. Lipman - 14 Feb 2025 Form 3 Insider Report for Capstone Holding Corp. (CAPS)
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- CAPS
- Reported as of
- 14 Feb 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 22 Apr 2025, 15:53:49 UTC
- Prior SEC filing
- 10 Dec 2024
- Next SEC filing
- 22 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew E. Lipman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew E. Lipman filed Form 3 for Capstone Holding Corp. (CAPS) on 22 Apr 2025.
Change
- Previous filing in this sequence was filed on 10 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CAPS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,650,436
- Date
- 14 Feb 2025
- Ownership
- See Footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CAPS
holding
Derivative
Common Stock Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 14 Feb 2025
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 6,322
- Exercise price
- $75.00
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of (i) 121,774 shares controlled by Matthew Lipman, through his control of BP Peptides, LLC. Brookstone Acquisition Partners XXI Corporation owns 81% of BP Peptides, LLC. Mr. Lipman owns approximately 4% of Brookstone Acquisition Partners XXI Corporation; and (ii) 2,528,662 shares of Common Stock owned by BPA XIV, LLC, an entity controlled by Matthew Lipman.
Footnote F2
Includes a warrant to purchase up to 6,322 shares of Common Stock issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC which is controlled by Matthew Lipman and Michael Toporek.